Top-News
Freitag,
18.05.2018 13:00
von
PR Newswire
| Aufrufe: 47
VIDEO: Bionomics Limited CEO & Managing Director Dr. Deborah Rathjen Featured in OTCQX Video Series
Zwei Frauen beim Shopping (Symbolbild).
© filadendron / E+ / Getty Images
PR Newswire
NEW YORK, May 18, 2018
NEW YORK, May 18, 2018 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQX: BNOEF) CEO & Managing Director Dr. Deborah Rathjen was interviewed by OTC Markets Group (OTCQX: OTCM) in its prominent OTCQX® Video Series. The series features interviews with senior executives of OTCQX companies as they showcase their businesses and investment profiles.
In the interview, Dr. Rathjen discusses:
- How Bionomics harnesses innovation to enhance the drug pipeline
- The company's recent R&D collaboration for the treatment of cognitive dysfunction in Alzheimer's patients
- How trading on OTCQX has helped Bionomics Limited to further its strategic objectives
To watch the complete interview, visit OTC Markets Group's YouTube page at
https://www.youtube.com/watch?v=luxgeClnAtg
About Bionomics Limited
Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder and for posttraumatic
stress disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada).
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 10,000 U.S. and global securities. Through OTC Link® ATS and OTC Link ECN, we connect a diverse network of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.
To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.
OTC Link ATS and OTC Link ECN are operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
Subscribe to the OTC Markets RSS Feed
The information contained in this press release and in the video to which it refers is provided "as is" for educational and informational purposes only and should not serve as the basis for any trading or investing decisions. OTC Markets Group makes no representations and disclaims all express, implied and statutory warranties of any kind to any viewer or third party. Neither OTC Markets Group nor any of its affiliates makes any endorsement of any particular company, security, product or financial strategy, and nothing contained in this video should be construed as investment advice. Investors should undertake their own diligence and carefully evaluate companies before investing.
Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com
View original content with multimedia:http://www.prnewswire.com/news-releases/video-bionomics-limited-ceo--managing-director-dr-deborah-rathjen-featured-in-otcqx-video-series-300650636.html
SOURCE OTC Markets Group Inc.
Werbung
Mehr Nachrichten zur Otc Markets Group Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
